Study #2022-1058
A prospective study on the real life experience in the treatment of mild to moderate COVID-19 with Molnupiravir in immunocompromised adult (>18 years of age) patients with cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Study on the real life experience in the treatment of mild to moderate COVID-19 with Molnupiravir
Resources and Links
Phone Number: 1-877-MDA-6789
clinicaltrials.gov NCT No: N/A
Information and next steps
Disease:
Unknown Sites
Study phase:
Not applicable
Physician name:
Issam Raad
Department:
Infectious Diseases
For general questions about clinical trials:
1-833-419-2004
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.